p53 immunostaining pattern in Brazilian patients with hepatocellular carcinoma

Authors

  • Venâncio Avancini Ferreira Alves São Paulo University; Adolfo Lutz Institute; School of Medicine & Immunohistochemistry Laboratory; Department of Pathology
  • Marcelo Eidi Nita São Paulo University; Adolfo Lutz Institute; School of Medicine & Immunohistochemistry Laboratory; Department of Pathology
  • Flair José Carrilho São Paulo University; School of Medicine; Department of Gastroenterology
  • Suzane Kioko Ono-nita São Paulo University; School of Medicine; Department of Gastroenterology
  • Alda Wakamatsu São Paulo University; Adolfo Lutz Institute; School of Medicine & Immunohistochemistry Laboratory; Department of Pathology
  • Dárcio Matenhauer Lehrbach São Paulo University; Adolfo Lutz Institute; School of Medicine & Immunohistochemistry Laboratory; Department of Pathology
  • Maria Fernanda Pimentel de Carvalho São Paulo University; Adolfo Lutz Institute; School of Medicine & Immunohistochemistry Laboratory; Department of Pathology
  • Evandro Sobroza de Mello São Paulo University; Adolfo Lutz Institute; School of Medicine & Immunohistochemistry Laboratory; Department of Pathology
  • Luiz Carlos da Costa Gayotto São Paulo University; Adolfo Lutz Institute; School of Medicine & Immunohistochemistry Laboratory; Department of Pathology
  • Luiz Caetano da Silva São Paulo University; School of Medicine; Department of Gastroenterology

Keywords:

Liver cancer, p53, Cell cycle, Apoptosis, Hepatitis B, Hepatitis C, Immunohistochemistry

Abstract

Hepatocellular carcinoma (HCC) is an important type of cancer etiologically related to some viruses, chemical carcinogens and other host or environmental factors associated to chronic liver injury in humans. The tumor suppressor gene p53 is mutated in highly variable levels (0-52%) of HCC in different countries. OBJECTIVE: The objective of the present study was to compare the frequency of aberrant immunohistochemical expression of p53 in HCC occurring in cirrhotic or in non-cirrhotic patients as well as in liver cell dysplasia and in adenomatous hyperplasia. We studied 84 patients with HCC or cirrhosis. RESULTS: We detected p53 altered immuno-expression in 58.3% of patients in Grade III-IV contrasting to 22.2% of patients in Grade I-II (p = 0.02). Nontumorous areas either in the vicinity of HCC or in the 30 purely cirrhotic cases showed no nuclear p53 altered expression, even in foci of dysplasia or adenomatous hyperplasia. No significant difference was found among cases related to HBV, HCV or alcohol. CONCLUSION: The high frequency of p53 immunoexpression in this population is closer to those reported in China and Africa, demanding further studies to explain the differences with European and North American reports.

Downloads

Download data is not yet available.

Downloads

Published

2004-02-01

Issue

Section

Liver Cancer

How to Cite

Alves, V. A. F., Nita, M. E., Carrilho, F. J., Ono-nita, S. K., Wakamatsu, A., Lehrbach, D. M., Carvalho, M. F. P. de, Mello, E. S. de, Gayotto, L. C. da C., & Silva, L. C. da. (2004). p53 immunostaining pattern in Brazilian patients with hepatocellular carcinoma . Revista Do Instituto De Medicina Tropical De São Paulo, 46(1), 25-31. https://revistas.usp.br/rimtsp/article/view/30776